HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 317 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $478,675 | +3.9% | 9,142 | -19.3% | 0.15% | +8.0% |
| Q1 2024 | $460,579 | +55.9% | 11,322 | +41.7% | 0.14% | +44.2% |
| Q4 2023 | $295,347 | -3.2% | 7,991 | 0.0% | 0.10% | -15.2% |
| Q3 2023 | $305,256 | +5.9% | 7,991 | 0.0% | 0.11% | +14.3% |
| Q2 2023 | $288,235 | +43.6% | 7,991 | +52.1% | 0.10% | +32.4% |
| Q1 2023 | $200,688 | -34.6% | 5,255 | -32.4% | 0.07% | -45.6% |
| Q3 2022 | $307,000 | +12.5% | 7,769 | +25.3% | 0.14% | +20.4% |
| Q2 2022 | $273,000 | +33.8% | 6,199 | +21.4% | 0.11% | +63.8% |
| Q1 2022 | $204,000 | -11.3% | 5,108 | -10.6% | 0.07% | 0.0% |
| Q4 2021 | $230,000 | -0.9% | 5,712 | 0.0% | 0.07% | -5.5% |
| Q3 2021 | $232,000 | -10.4% | 5,712 | 0.0% | 0.07% | -8.8% |
| Q2 2021 | $259,000 | +8.8% | 5,712 | 0.0% | 0.08% | +6.7% |
| Q1 2021 | $238,000 | – | 5,712 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $206,177,000 | 28.12% |
| BB BIOTECH AG | 8,322,860 | $121,763,000 | 3.90% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 398,633 | $4,579,000 | 2.84% |
| DOHENY ASSET MANAGEMENT /CA | 227,193 | $3,324,000 | 2.43% |
| SNYDER CAPITAL MANAGEMENT L P | 2,833,759 | $41,458,000 | 2.24% |
| First Light Asset Management, LLC | 938,399 | $13,729,000 | 2.19% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,027,164 | $132,067,000 | 1.77% |
| Taylor Wealth Management Partners | 204,277 | $2,989,000 | 1.72% |
| Sterling Global Strategies LLC | 22,000 | $321,860,000 | 1.63% |
| Granite Investment Partners, LLC | 988,939 | $14,468,000 | 1.06% |